Advanced MRI biomarkers for efficient detection and monitoring of Corticobasal Degeneration (CBD) progression in clinical trials

Advanced MRI methodologies, combining volumetric and diffusion-based analyses, enable precise tracking of CBD progression and differentiation from PSP. This approach minimizes sample size requirements, can potentially accelerate clinical trials, and facilitates early evaluation of disease-modifying therapies. The integration of robust imaging biomarkers into clinical trials is critical for improving diagnostic accuracy and therapeutic interventions for rare neurodegenerative diseases, like CBD.